BioLife Solutions Reports Second Quarter 2018 Preliminary Revenue of $5.2 Million, up 103% Year-over-Year and 36% Sequentially
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioLife Solutions (BLFS) PT Raised to $18 at Maxim Group as Cell Media Revs Beat Expecations
July 2, 2018 11:04 AM EDTMaxim Group raised its price target on BioLife Solutions (NASDAQ: BLFS) to $18.00 (from $12.00) while maintaining a Buy rating.
Analyst Jason McCarthy highlighted:
BioLife shares are up today (15%+) following the company's announcement of preliminary cell preservation media revenue for 2Q18 coming in at $5.2M, up 36% sequentially and 103% y/y. The company raised guidance to $18.5M-$20M, from $14.5M-$15.5M. The company is... MoreBioLife Solutions (BLFS) Reports Prelim. 2Q Revenues Above Consensus; Boosts FY18 Revenue Guidance
July 2, 2018 8:10 AM EDTBioLife Solutions (NASDAQ: BLFS) reported Q2 revenue for the quarter came in at $5.2 million versus the consensus estimate of $3.7 million.
BioLife CEO Mike Rice commented, "Strong product demand during the second quarter from our cell and gene therapy customers in the regenerative medicine market segment resulted in more than 100% revenue growth over the prior-year period. Given our performance for the first half of 2018, increased adoption of our products in cell therapy clinical trials, and our outlook on product demand for the remainder of the year, we are significantly... More
